Dr Richard Bax

Dr Richard Bax

Dr Richard Bax on LinkedIn

Senior Advisor

Dr Bax has worked in the pharmaceutical industry for 30 years, particularly in the antibiotic arena. Of particular relevance to Helperby Therapeutics, he helped to develop Bactroban (topical) whilst head of antibiotic development at SmithKline.

Until 2006, he was Chief Scientific Officer of Biosyn, Inc., a research and development (R&D) Biotechnology Company involved in the R&D of microbicides (topical vaginal gels used by women to prevent the acquisition of human immunodeficiency virus (HIV) and other sexually transmitted diseases).

He qualified at the Royal Free Hospital, London, in 1970, and then spent two years in hospital medicine and five years in family practice. In 1977, he joined Glaxo Research and spent the next 23 years in Glaxo, Roussel, Lilly, ICI Pharmaceuticals and then nine years as global head of SmithKline Global Clinical Development.

He was intimately involved in the development, registration and medical marketing of cefuroxime, gentamicin, tobramycin, cefotaxime, cefaclor, vancomycin, cefotetan, bactroban and meropenem. He gave the first dose of cefuroxime axetil and meropenem to the first human subjects. He was head of development Europe for Chiron Biopharma and a member of the global development group in Emmeryville, California from Jan 2004 to August 2006 where he was responsible for the phase 1 studies of 2 anticancer products, a new formulation of TOBI and for the European development of daptomycin culminating in a successful EU license in November 2005.

He was the founder and treasurer of the Faculty of Pharmaceutical Medicine based at the Royal College of Physicians of London. Dr Bax was a board member of the British Society of Antimicrobial Agents and Chemotherapy (1984–1988) and is the UK representative of the board of the European Society of Clinical Microbiology and Infectious Diseases (ESMID).

In 2002, he was a consultant to the office of AIDS Research (OAR) on microbicides in Washington and has served on other advisory boards, including the EU Working Party on Bacterial Resistance, the World Health Organization (WHO) and the International Federation of Pharmaceutical Manufacturers Association, as well as scientific advisory boards on pharmaceutical companies, researching and developing new anti-infectives. He has more than 100 publications on antimicrobial R&D, including the art and science of clinical trials and how to assess the impact of bacterial resistance on clinical outcome.